Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Kezar Life Sciences (KZR) Receivables - Accured (2022 - 2024)

Kezar Life Sciences (KZR) has disclosed Receivables - Accured for 3 consecutive years, with $589000.0 as the latest value for Q3 2024.

  • For Q3 2024, Receivables - Accured changed N/A year-over-year to $589000.0; the TTM value through Sep 2024 reached $589000.0, changed N/A, while the annual FY2023 figure was $695000.0, 10.21% down from the prior year.
  • Receivables - Accured hit $589000.0 in Q3 2024 for Kezar Life Sciences, up from $374000.0 in the prior quarter.
  • Across five years, Receivables - Accured topped out at $774000.0 in Q4 2022 and bottomed at $374000.0 in Q2 2024.
  • Average Receivables - Accured over 3 years is $616000.0, with a median of $648000.0 recorded in 2024.
  • On a YoY basis, Receivables - Accured climbed as much as 10.21% in 2023 and fell as far as 10.21% in 2023.
  • Kezar Life Sciences' Receivables - Accured stood at $774000.0 in 2022, then decreased by 10.21% to $695000.0 in 2023, then fell by 15.25% to $589000.0 in 2024.
  • According to Business Quant data, Receivables - Accured over the past three periods came in at $589000.0, $374000.0, and $648000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.